Heinz-Josef Lenz, MD

University Professor of Medicine and Cancer Biology

J. Terrence Lanni Chair in Gastrointestinal Cancer Research

Co-Director, USC Center for Molecular Pathway and Drug Discovery

Co-Director of the USC Norris Center for Cancer Drug Development

Image of Heinz-Josef Lenz, MD
Is this your profile? Click to edit

Overview

Heinz-Josef Lenz, M.D., FACP, is the Associate Director for Clinical Research and Co-Leader of the Gastrointestinal Cancers Program at the USC Norris Comprehensive Cancer Center. Dr. Lenz is Professor of Medicine and Preventive Medicine, Section Head of GI Oncology in the Division of Medical Oncology and Co-Director of the Colorectal Center at the Keck School of Medicine of the University of Southern California.

Dr. Lenz received his medical degree from Johannes-Gutenberg Universität in Mainz, Germany, in 1985. He completed a residency in Hematology and Oncology at the University Hospital Tübingen in Germany, a clerkship in Oncology at George Washington University in Washington, DC, and a clerkship in Hematology at Beth Israel Hospital of Harvard Medical School in Boston, Massachusetts. He served subsequent fellowships in Biochemistry and Molecular Biology at the USC Norris Comprehensive Cancer Center.

An active researcher, Dr. Lenz focuses on topics including the regulation of gene expression involved in drug resistance, patients at high risk of developing colorectal cancer, and determination of carcinogenesis, methods of early detection, and better surveillance of these cancers. He is a member of several professional societies, including the American Association for Cancer Research, the American Gastroenterology Association, and the National Society of Genetic Counselors. He also serves on the National Advisory Board of a number of professional organizations. Dr. Lenz is the author of numerous peer-reviewed publications and invited papers, reviews, and editorials. He also serves as Co-Chair of the GI Committee and Correlative Science Committee for SWOG. He is a member of the NCI Task Force for Gastroesophageal Cancer, the NCI Steering Committee and the NCI Translational Science Committee. In addition to having an NCI-funded laboratory, he was a recipient of the ASCO Young Investigator Award, the ASCO Career Development Award, and the STOP Cancer Career Development Award. He received in 2021 the USC Mentoring Award as well as highly cited researchers in the world. He has been select as influential leader by the LA Business Journal in 2021 and 2023.

As Deputy Cancer Center Director for Research Programs and Co-Director for the Center for Cancer Drug Development, Dr. Lenz oversees the programmatic and clinical activities of the Gastrointestinal Cancers, Genitourinary Cancers, Women’s Cancers, and Leukemia and Lymphoma Programs.

Awards

  • Conquer Cancer Foundation: ASCO Young Investigator Award, 1994
  • Conquer Cancer Foundation: ASCO Career Development Award, 1995
     – 1998
  • STOP CANCER: Career Development Award
  • USC: Bob Chandler Courage Award, 2003
  • 2003 Annual Retreat on Cancer Research: The Gallo Award, 2003
  • The WunderGlo Foundation: 1st Annual Cancer Warrior Award, 2012
  • Western Society of Clinical Investigation: Outstanding Investigator Award, 2016
  • USC: USC Mentoring Award for Postdoctoral Fellows, 2021

Publications

  • Long non-coding RNAs in colorectal cancer: shaping the tumour microenvironment and advancing precision oncology. Nat Rev Gastroenterol Hepatol. 2026 Sep 01.. View in PubMed
  • Extended Follow-Up of Botensilimab Plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer Without Active Liver Metastases. Clin Cancer Res. 2026 Aug 28.. View in PubMed
  • Dihydropyrimidine dehydrogenase modulates immune response to checkpoint inhibition in mismatch repair deficient/microsatellite instability-high colorectal cancer. J Immunother Cancer. 2026 Aug 17; 14(8).. View in PubMed
  • MammaTrace – a tumor naïve cell-free DNA methylation test for minimal residual disease in breast cancer. NPJ Precis Oncol. 2026 Jul 23; 10(1).. View in PubMed
  • Next-generation precision oncology in microsatellite stable colorectal cancer: integrated targeting beyond RAS and RAF. ESMO Open. 2026 Aug; 11(8):108304.. View in PubMed
  • Targeting WRN Helicase in Microsatellite Instable Colorectal Cancer Induces Antitumor Immunity through Extrachromosomal Circular DNA Release. Cancer Res. 2026 Jul 16.. View in PubMed
  • A DR5/Ligase 3-mediated feedback loop perpetuates immunogenicity in mismatch repair deficient colorectal cancer. Gastroenterology. 2026 Jul 16.. View in PubMed
  • Genomic analysis of oesophageal carcinoma (EC) identifies recurrent mutations in histone methyltransferases as a distinctive subset. Oncogene. 2026 Sep; 45(33):3472-3478.. View in PubMed
  • Phase 2 dose-expansion trial of OBI-3424, a DNA-alkylating prodrug, in patients with advanced solid tumors expressing AKR1C3. Oncologist. 2026 Jul 08; 31(8).. View in PubMed
  • Activation of the endocytosis pathway stratifies subtypes and therapeutic sensitivity in colorectal cancer. Res Sq. 2026 Jul 05.. View in PubMed